“That’s going to be driven by continued consistency of supply, which we expect, which has already improved across the portfolio and will continue to improve.”

In context

“re these three pieces – what are you assuming for those three buckets? And I think you mentioned the renal impact in Q4. Could you specify that? And Geoff, for you, I understand you’re not giving fiscal ‘24 guidance, but when you think about the incremental changes, right, what are the positive tailwinds and negative headwinds? Is China still declining in fiscal ‘24? What happens to Diabetes? Is that on the plus side or minus side? And any other plus or minus at a high level would be helpful. Karen Parkhill: Yes, Vijay, let me take the first part of your question. In terms of our Q4 revenue ramp, when we gave our second half guidance last quarter, we expected sequential improvement from the third quarter into the fourth quarter. And obviously, we’re still expecting sequential improvement. That’s going to be driven by continued consistency of supply, which we expect, which has already improved across the portfolio and will continue to improve. We also have some recent product launches, like Evolut FX and Hugo, which will continue to ramp. You may recall, we have our harmony Harmony valve, which will return to market as well. And then we’ve also got some launches into new markets, like diabetic neuropathy that will begin to take some hold. And we’ve got reduced headwinds from things like vents and VBP in the quarter. You asked specifically about Renal Care. We do expect to close that joint venture with DaVita in the fourth quarter. So we simply noted that when we guided so that we didn’t force you all to change your models mid-quarter. We just put it in now. I hope that helps. Geoff Martha: Just to finish off – just to highlight one thing in Karen’s commentary there. A big one will be continued turnaround of our Surgical Innovat”